Abdera Therapeutics
- 24/04/2023
- Series B
- $142,000,000
Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid development of a broad range of safe and efficacious therapies serving cancer patients with limited treatment options.
Abdera Therapeutics is growing rapidly and seeking key new team members who thrive at the cutting-edge of innovation. Come join us and be a part of the ground-breaking team set to unlock the power of targeted radiotherapy!
- Industry Biotechnology Research
- Website https://abderatx.com/
- LinkedIn https://www.linkedin.com/company/abdera-therapeutics/
Related People
Lori Lyons-WilliamsFounder
President and Chief Executive Officer with responsibilities and experience spanning strategy, operations, corporate governance, private and public financings, partnerships, mergers and acquisitions.
Active on Boards of Directors: Director, a stealth company; Independent Director at RAPT Therapeutics (NASDAQ: RAPT, Compensation Committee and Nominating and Corporate Governance Committee); Pipeline Therapeutics (private); former independent director at Five Prime Therapeutics, (NASDAQ: FPRX, Audit and Compensation Committee experience) until its 2021 acquisition by Amgen.
Successful exits:
Chief Commercial Officer at Dermira (NASDAQ: DERM), acquired by Eli Lilly for $1.1B in 2020
Independent Director at Five Prime Therapeutics (NASDAQ: FPRX), acquired by Amgen for $1.9B in 2021